摘要
乳腺癌作为女性最常见的一类恶性疾病,其生物治疗成为了继手术治疗、放射治疗、化学治疗后的一种新兴的治疗手段。乳腺癌生物技术药物的研发,近年来取得了令人瞩目的进展,目前FDA已批准了3种单克隆抗体药物,分别为曲妥珠单抗、帕妥珠单抗和Kadcyla(T-DM1),十二种抗体药物正在临床研究中。本文就FDA审批通过的以及正在进行临床研究的治疗乳腺癌的抗体药物做一综述。
As the most common type of malignant disease in women, biological treatment of breast cancer has become a new treatment in addition to surgery, radiotherapy and chemotherapy. In recent years, a remarkable progress has also been achieved in the antibody drugs for treating breast cancer. Three monoclonal antibodies （trastuzumab, pertuzumab and kadcyla） have been approved, and more than 12 antibodies are studied in clinical trials. In this review, the research progress of approved biologics and those in clinical trials were introduced.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第23期2734-2738,共5页
Chinese Journal of New Drugs
基金
重庆市科技攻关计划资助项目(cstc2013jcsf10002)
关键词
乳腺癌
抗体药物
FDA
临床研究
breast cancer
antibody drugs
FDA
clinical trials
